Portfolio manager Laura Mayfield says some individual investors “are focused on the dividend-yield return, but some might be ...

Software maker Adobe was on the receiving end of a downgrade to sell, with the analyst arguing generative artificial ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Paramount bought and cancelled about 5.67 million shares under its current buyback program, which authorized it to repurchase up to 7.89 million shares through July 7. The natural gas producer's ...